Modern medicine firmly recognizes psoriasis not as a localized skin condition, but as a chronic systemic immune-mediated inflammatory disease linked to cardiovascular, metabolic, and articular comorbidities.

The Hyper-Accelerated Epidermis

In healthy skin, epidermal keratinocytes mature and transit from the basal layer to the stratum corneum over 28 to 30 days. In plaque psoriasis, this cycle is shortened to just 3 to 5 days. Unable to shed naturally, immature nucleated keratinocytes accumulate as thick, well-demarcated erythematous plaques topped with silvery micaceous scales.

The IL-23 / IL-17 Axis: The Core Immunological Engine

The driving engine of psoriasis is an activated cytokine cascade:

  • Antigen-presenting dendritic cells produce Interleukin-23 (IL-23).
  • IL-23 expands and sustains pathogenic Th17 helper T-cells.
  • Th17 cells release large quantities of Interleukin-17 (IL-17) and TNF-alpha, provoking rapid keratinocyte hyper-proliferation and recruiting neutrophils to form Munro's microabscesses.

The Modern Biologic Revolution

For moderate-to-severe plaque psoriasis, targeted monoclonal antibodies have redefined treatment targets, transforming expectations from simple relief to complete skin clearance (PASI 90 and PASI 100):

  • IL-23 Inhibitors (e.g., Guselkumab, Risankizumab): Provide exceptional clinical clearance with infrequent dosing (every 8 to 12 weeks).
  • IL-17 Inhibitors (e.g., Secukinumab, Ixekizumab): Offer rapid plaque resolution and substantial relief from concomitant Psoriatic Arthritis.

Frequently Asked Questions

Can psoriasis affect the joints?

Yes. Up to 30% of patients with psoriasis develop Psoriatic Arthritis (PsA), causing joint stiffness, dactylitis (sausage digits), and enthesitis. Early systemic therapy is vital to prevent irreversible structural joint damage.

Is psoriasis contagious through direct contact?

No. Psoriasis is an autoimmune inflammatory condition driven by internal genetic and immunological factors; it is entirely non-contagious.